Suven Pharmaceuticals Ltd - 543064 - Closure of Trading Window
Intimation of closure of Trading Window28-06-2024
28-06-2024
Suven Pharmaceuticals Ltd - 543064 - Transcript Of The Conference Call For Acquisition Of A Majority Stake In Sapala Organics
Transcript of the conference call for acquisition of a majority stake in Sapala Organics21-06-2024
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for DB Trustee (Hong Kong) Ltd21-06-2024
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our conference call intimation dated June 13, 2024, the audio recording of the conference call for acquisition of a majority stake in Sapala Organics held on Wednesday, June 19, 2024, has been uploaded on the Company''s website19-06-2024
Suven Pharmaceuticals Business Update Call
Conference Call with Suven Pharmaceuticals Management and Analysts to discuss the acquisition of Sapala Organics. Listen to the full transcript.19-06-2024
Suven Pharmaceuticals Ltd - 543064 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on June 18, 2024 for Berhyanda Ltd & Berhyanda Midco Ltd19-06-2024
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CSCGlobal Capital Markets Singapore Pte Ltd19-06-2024
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 18, 2024 for Berhyanda Ltd & Berhyanda Midco Ltd18-06-2024
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 18, 2024 for Berhyanda Ltd & Berhyanda Midco Ltd18-06-2024
Suven Pharmaceuticals Ltd - 543064 - Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Update on amalgamation of Casper Pharma Pvt Ltd (WOS) into and with Suven Pharmaceuticals Limited is attached.15-06-2024